表紙
市場調查報告書

全球心血管藥市場 - 產業分析,市場規模,佔有率,成長,趨勢,預測 2017年∼2025年

Cardiovascular Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

出版商 Transparency Market Research 商品編碼 577676
出版日期 內容資訊 英文 241 Pages
商品交期: 最快1-2個工作天內
價格
全球心血管藥市場 - 產業分析,市場規模,佔有率,成長,趨勢,預測 2017年∼2025年 Cardiovascular Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025
出版日期: 2018年03月06日內容資訊: 英文 241 Pages
簡介

本報告提供全球心血管藥市場相關調查,提供市場概要,各醫藥品級·適應症·流通管道·地區的市場趨勢,市場規模的變化與預測,市場成長·阻礙因素以及市場機會分析,市場佔有率,競爭情形,主要企業的簡介等全面資訊。

目錄

第1章 簡介

  • 市場定義和範圍
  • 市場區隔
  • 主要的調查目的
  • 調查的重點

第2章 前提條件與調查方法

第3章 摘要整理

第4章 市場概要

  • 簡介
    • 醫藥品級定義
    • 產業的發展趨勢
  • 概要
  • 市場動態
    • 成長要素
    • 阻礙因素
    • 市場機會
  • 市場分析與預測
    • 收益額的預測
  • 供給需求方案
  • 波特的五力分析
  • 市場預測

第5章 全球心血管藥市場分析與預測:各醫藥品級

  • 簡介
  • 主要的觀察
  • 市場規模的變化與預測:各醫藥品級
    • 腎素 - 血管緊張素系抑制劑
    • 交感神經β受體阻斷劑
    • 利尿劑
    • 抗凝固劑
    • 抗高血脂症
    • 其他抗痙攣藥
    • 鈣拮抗劑
    • 其他
  • 市場魅力分析:各醫藥品級

第6章 全球心血管藥市場分析與預測:各適應症

  • 簡介
  • 主要的觀察
  • 市場規模的變化與預測:各適應症
    • 高血壓
    • 高血脂症
    • 冠狀動脈疾病
    • 週邊動脈疾病
    • 心律不整
    • 其他
  • 市場魅力分析:各適應症

第7章 全球心血管藥市場分析與預測:各流通管道

  • 簡介
  • 主要的觀察
  • 市場規模的變化與預測:各流通管道
    • 醫院藥局
    • 零售藥局
    • 線上藥局
  • 市場魅力分析:各流通管道

第8章 全球心血管藥市場分析與預測:各地區

  • 主要的觀察
  • 市場規模:各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 南美
    • 中東·非洲
  • 市場魅力分析:各地區

第9章 北美

第10章 歐洲

第11章 亞太地區

第12章 南美

第13章 中東·非洲

第14章 競爭情形

  • 企業的競爭情形
  • 企業佔有率分析
  • 企業簡介(詳細內容 - 概要,財務,最新趨勢,策略)
    • AstraZeneca
    • Pfizer Inc.
    • Novartis AG
    • Merck & Co. Inc.
    • Bristol-Myers Squibb Company
    • Bayer AG
    • Sanofi
    • Boehringer Ingelheim GmbH
    • F. Hoffmann-La Roche Ltd.
    • Abbott Laboratories
    • Gilead Sciences, Inc.
    • Johnson & Johnson
    • Astellas Pharma Inc.
    • Eli Lilly and Company
    • 大塚製藥
    • 武田藥品

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Title:
Cardiovascular Drugs Market (Drug Class - Anti hyperlipidemics, Anti-hypertensives, Anti-coagulants, Anti-fibrinolytics, Anti-arrhythmic; Distribution Channels - Hospital Pharmacies, Online Pharmacies, Retail Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025.

Global Cardiovascular Drugs Market: Overview

Cardiovascular drugs are widely used for treating various heart related dysfunction. With increasing number of cardiovascular diseases across the globe is the major driving factor for the growth of the cardiovascular diseases. According to the study conducted by Global Burden of Diseases estimate that the death rate due to CVD is 235 per 100000 in global population. According to WHO, cardiovascular diseases account for 31% deaths globally which is approximately 17.7 million individuals. Out of these 80% of the CVD deaths are due to stroke and heart attacks. Factors such as sedentary lifestyle, excess consumption of alcohol, stress, unhealthy eating habits, smoking are all factors responsible for the increase in the number of cardiovascular disorders among young population too.

The global cardiovascular drugs market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on drug class, indication, distribution channel and geography. A detailed qualitative analysis of drivers and restraints of the market and opportunities has been provided in the market overview section. In addition, the section comprises competitive matrix and company profiles with business overview to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis, by geography and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global cardiovascular drugs market.

Global Cardiovascular Drugs Market: Key Segments

Based on drug class the global cardiovascular drugs market is segmented into renin-angiotensin system blockers, beta blockers, diuretics, anti-clotting agents (anti-coagulants and platelet aggregation inhibitors), antihyperlipidemics, other antihypertensive, calcium channel blockers and others. The renin-angiotensin system blockers segment is further classified into ACE inhibitors and angiotensin receptor blockers and the anti-clotting agents segment is further segmented into anti-coagulants and platelet aggregation inhibitors. The drug class segments have been analyzed based on incidence of diseases, awareness regarding early diagnosis and presence of key players in the region. The market size and forecast for each of these segments have been provided for the period from 2015 to 2025, along with their respective CAGRs for the forecast period from 2017 to 2025, considering 2016 as the base year.

According to indication the global cardiovascular drugs market is segmented into hypertension, hyperlipidemia, coronary artery diseases, peripheral artery disease, arrhythmia and others. The market size and forecast for each of these segments have been provided for the period from 2015 to 2025, along with their respective CAGRs for the forecast period from 2017 to 2025, considering 2016 as the base year.

Global Cardiovascular Drugs Market: Regional Outlook

Geographically, the global cardiovascular drugs market has been categorized into five major regions and the key countries in the respective region: North America (the U.S., Canada), Europe (the U.K., Germany, France, Italy, Spain and Rest of Europe), Asia Pacific (China, Japan, India, Australia & New Zealand and Rest of Asia Pacific), Latin America (Brazil, Mexico and Rest of Latin America) and Middle East & Africa (South Africa, GCC Region, Israel and Rest of Middle East & Africa). The market size and forecast for each of these regions and the mentioned countries have been provided for the period from 2015 to 2025, along with their respective CAGRs for the forecast period from 2017 to 2025, considering 2016 as the base year. The research study also covers the competitive scenario in these regions.

Companies Mentioned in Report

The report also profiles the major players in the market and provides various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major companies profiled in the cardiovascular drugs market are AstraZeneca, Pfizer Inc., Novartis AG, Merck & Co. Inc., Bristol-Myers Squibb Company, Bayer AG, Sanofi, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd., Abbott Laboratories, Gilead Sciences, Inc., Johnson & Johnson, Astellas Pharma, Inc., Eli Lilly and Company, Otsuka Holdings Co., Ltd., Takeda Pharmaceuticals Company Limited and others.

The global cardiovascular drugs market has been segmented as follows:

  • Cardiovascular Drugs Market, by Drug Class
  • Renin-Angiotensin System Blockers
  • ACE Inhibitors
  • Angiotensin Receptor Blockers
  • Beta Blockers
  • Diuretics
  • Anti-Clotting Agents
  • Anti-Coagulants
  • Platelet Aggregation Inhibitors
  • Antihyperlipidemics
  • Other Antihypertensive
  • Calcium Channel Blockers
  • Others
  • Cardiovascular Drugs Market, by Indication
  • Hypertension
  • Hyperlipidemia
  • Coronary Artery Disease
  • Peripheral Artery Disease
  • Arrhythmia
  • Others
  • Cardiovascular Drugs Market, by Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Cardiovascular Drugs Market, by Geography
  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest of Europe
  • Asia Pacific
  • Japan
  • China
  • India
  • Australia & New Zealand
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East and Africa
  • South Africa
  • GCC Region
  • Israel
  • Rest of Middle East & Africa

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global CVD Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Drug Class Definition
    • 4.1.2. Industry Developments
  • 4.2. Overview
  • 4.4. Market Dynamics
    • 4.4.1. Drivers
    • 4.4.2. Restraints
    • 4.4.3. Opportunities
  • 4.5. Global CVD Market Analysis and Forecasts, 2015-2025
    • 4.5.3. Market Revenue Projections (US$ Mn)
  • 4.6. CVD Market - Global Supply Demand Scenario
  • 4.7. Porter's Five Force Analysis
  • 4.9. Market Outlook

5. Global CVD Market Analysis and Forecasts, By Drug Class

  • 5.1. Introduction & Definition
  • 5.2. Key Findings
  • 5.4. Market Value Forecast By Drug Class , 2015-2025
    • 5.4.1. Renin-Angiotensin System Blockers
      • 5.4.1.1. ACE Inhibitors
      • 5.4.1.2. Angiotensin Receptor Blockers
    • 5.4.2. Beta Blockers
    • 5.4.3. Diuretics
    • 5.4.4. Anti-Clotting Agents
      • 5.4.4.1. Anti-Coagulants
      • 5.4.4.2. Platelet Aggregation Inhibitors
    • 5.4.5. Antihyperlipidemics
    • 5.4.6. Other Antihypertensives
    • 5.4.7. Calcium Channel Blockers
    • 5.4.8. Others
  • 5.5. Market Attractiveness By Drug Class

6. Global CVD Market Analysis and Forecasts, By Indications

  • 6.1. Introduction & Definition
  • 6.2. Key Findings
  • 6.4. Market Value Forecast By Indications , 2015-2025
    • 6.4.1. Hypertension
    • 6.4.2. Hyperlipidemia
    • 6.4.3. Coronary Artery Disease
    • 6.4.4. Peripheral Artery Disease
    • 6.4.5. Arrhythmia
    • 6.4.6. Others
  • 6.5. Market Attractiveness By Indications

7. Global CVD Market Analysis and Forecasts, By Distribution Channel

  • 7.1. Introduction & Definition
  • 7.2. Key Findings
  • 7.4. Market Value Forecast By Distribution Channel , 2015-2025
    • 7.4.1. Hospital Pharmacy
    • 7.4.2. Retail Pharmacy
    • 7.4.3. Online Pharmacy
  • 7.5. Market Attractiveness By Distribution Channel

8. Global CVD Market Analysis and Forecasts, By Region

  • 8.1. Key Findings
  • 8.2. Market Value Forecast By Region
    • 8.2.1. North America
    • 8.2.2. Europe
    • 8.2.3. Asia Pacific
    • 8.2.4. Latin America
    • 8.2.5. Middle East & Africa
  • 8.3. Market Attractiveness By Country/Region

9. North America CVD Market Analysis and Forecast

  • 9.1. Introduction
    • 9.1.1. Key Findings
  • 9.2. Market Value Forecast By Drug Class , 2015-2025
    • 9.2.1. Renin-Angiotensin System Blockers
      • 9.2.1.1. ACE Inhibitors
      • 9.2.1.2. Angiotensin Receptor Blockers
    • 9.2.2. Beta Blockers
    • 9.2.3. Diuretics
    • 9.2.4. Anti-Clotting Agents
      • 9.2.4.1. Anti-Coagulants
      • 9.2.4.2. Platelet Aggregation Inhibitors
    • 9.2.5. Antihyperlipidemics
    • 9.2.6. Other Antihypertensives
    • 9.2.7. Calcium Channel Blockers
    • 9.2.8. Others
  • 9.3. Market Value Forecast By Indications , 2015-2025
    • 9.3.1. Hypertension
    • 9.3.2. Hyperlipidemia
    • 9.3.3. Coronary Artery Disease
    • 9.3.4. Peripheral Artery Disease
    • 9.3.5. Arrhythmia
    • 9.3.6. Others
  • 9.4. Market Value Forecast By Distribution Channel , 2015-2025
    • 9.4.1. Hospital Pharmacy
    • 9.4.2. Retail Pharmacy
    • 9.4.3. Online Pharmacy
  • 9.5. Market Value Forecast By Country , 2015-2025
    • 9.5.1. U.S.
    • 9.5.2. Canada
  • 9.6. Market Attractiveness Analysis
    • 9.6.1. By Drug Class
    • 9.6.2. By Indications
    • 9.6.3. By Distribution Channel
    • 9.6.4. By Country

10. Europe CVD Market Analysis and Forecast

  • 10.1.Introduction
    • 10.1.1. Key Findings
  • 10.2.Market Value Forecast By Drug Class , 2015-2025
    • 10.2.1. Renin-Angiotensin System Blockers
      • 10.2.1.1. ACE Inhibitors
      • 10.2.1.2. Angiotensin Receptor Blockers
    • 10.2.2. Beta Blockers
    • 10.2.3. Diuretics
    • 10.2.4. Anti-Clotting Agents
      • 10.2.4.1. Anti-Coagulants
      • 10.2.4.2. Platelet Aggregation Inhibitors
    • 10.2.5. Antihyperlipidemics
    • 10.2.6. Other Antihypertensives
    • 10.2.7. Calcium Channel Blockers
    • 10.2.8. Others
  • 10.3. Market Value Forecast By Indications , 2015-2025
    • 10.3.1. Hypertension
    • 10.3.2. Hyperlipidemia
    • 10.3.3. Coronary Artery Disease
    • 10.3.4. Peripheral Artery Disease
    • 10.3.5. Arrhythmia
    • 10.3.6. Others
  • 10.4. Market Value Forecast By Distribution Channel , 2015-2025
    • 10.4.1. Hospital Pharmacy
    • 10.4.2. Retail Pharmacy
    • 10.4.3. Online Pharmacy
  • 10.5. Market Value Forecast By Country , 2015-2025
    • 10.5.1. Germany
    • 10.5.2. U.K.
    • 10.5.3. France
    • 10.5.4. Spain
    • 10.5.5. Italy
    • 10.5.6. Rest of Europe
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Drug Class
    • 10.6.2. By Indications
    • 10.6.3. By Distribution Channel
    • 10.6.4. By Country

11. Asia Pacific CVD Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast By Drug Class , 2015-2025
    • 11.2.1. Renin-Angiotensin System Blockers
      • 11.2.1.1. ACE Inhibitors
      • 11.2.1.2. Angiotensin Receptor Blockers
    • 11.2.2. Beta Blockers
    • 11.2.3. Diuretics
    • 11.2.4. Anti-Clotting Agents
      • 11.2.4.1. Anti-Coagulants
      • 11.2.4.2. Platelet Aggregation Inhibitors
    • 11.2.5. Antihyperlipidemics
    • 11.2.6. Other Antihypertensives
    • 11.2.7. Calcium Channel Blockers
    • 11.2.8. Others
  • 11.3. Market Value Forecast By Indications , 2015-2025
    • 11.3.1. Hypertension
    • 11.3.2. Hyperlipidemia
    • 11.3.3. Coronary Artery Disease
    • 11.3.4. Peripheral Artery Disease
    • 11.3.5. Arrhythmia
    • 11.3.6. Others
  • 11.4. Market Value Forecast By Distribution Channel , 2015-2025
    • 11.4.1. Hospital Pharmacy
    • 11.4.2. Retail Pharmacy
    • 11.4.3. Online Pharmacy
  • 11.5. Market Value Forecast By Country , 2015-2025
    • 11.5.1. Japan
    • 11.5.2. China
    • 11.5.3. India
    • 11.5.4. Australia & New Zealand
    • 11.5.5. Rest of Asia Pacific
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Drug Class
    • 11.6.2. By Indications
    • 11.6.3. By Distribution Channel
    • 11.6.4. By Country

12. Latin America CVD Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast By Drug Class , 2015-2025
    • 12.2.1. Renin-Angiotensin System Blockers
      • 12.2.1.1. ACE Inhibitors
      • 12.2.1.2. Angiotensin Receptor Blockers
    • 12.2.2. Beta Blockers
    • 12.2.3. Diuretics
    • 12.2.4. Anti-Clotting Agents
      • 12.2.4.1. Anti-Coagulants
      • 12.2.4.2. Platelet Aggregation Inhibitors
    • 12.2.5. Antihyperlipidemics
    • 12.2.6. Other Antihypertensives
    • 12.2.7. Calcium Channel Blockers
    • 12.2.8. Others
  • 12.3. Market Value Forecast By Indications , 2015-2025
    • 12.3.1. Hypertension
    • 12.3.2. Hyperlipidemia
    • 12.3.3. Coronary Artery Disease
    • 12.3.4. Peripheral Artery Disease
    • 12.3.5. Arrhythmia
    • 12.3.6. Others
  • 12.4. Market Value Forecast By Distribution Channel , 2015-2025
    • 12.4.1. Hospital Pharmacy
    • 12.4.2. Retail Pharmacy
    • 12.4.3. Online Pharmacy
  • 12.5. Market Value Forecast By Country , 2015-2025
    • 12.5.1. Brazil
    • 12.5.2. Mexico
    • 12.5.3. Rest of Latin America
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Drug Class
    • 12.6.2. By Indications
    • 12.6.3. By Distribution Channel
    • 12.6.4. By Country

13. Middle East & Africa CVD Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast By Drug Class , 2015-2025
    • 13.2.1. Renin-Angiotensin System Blockers
      • 13.2.1.1. ACE Inhibitors
      • 13.2.1.2. Angiotensin Receptor Blockers
    • 13.2.2. Beta Blockers
    • 13.2.3. Diuretics
    • 13.2.4. Anti-Clotting Agents
      • 13.2.4.1. Anti-Coagulants
      • 13.2.4.2. Platelet Aggregation Inhibitors
    • 13.2.5. Antihyperlipidemics
    • 13.2.6. Other Antihypertensives
    • 13.2.7. Calcium Channel Blockers
    • 13.2.8. Others
  • 13.3. Market Value Forecast By Indications , 2015-2025
    • 13.3.1. Hypertension
    • 13.3.2. Hyperlipidemia
    • 13.3.3. Coronary Artery Disease
    • 13.3.4. Peripheral Artery Disease
    • 13.3.5. Arrhythmia
    • 13.3.6. Others
  • 13.4. Market Value Forecast By Distribution Channel , 2015-2025
    • 13.4.1. Hospital Pharmacy
    • 13.4.2. Retail Pharmacy
    • 13.4.3. Online Pharmacy
  • 13.5. Market Value Forecast By Country , 2015-2025
    • 13.5.1. South Africa
    • 13.5.2. GCC Region
    • 13.5.3. Israel
    • 13.5.4. Rest of Middle East and Africa
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Drug Class
    • 13.6.2. By Indications
    • 13.6.3. By Distribution Channel
    • 13.6.4. By Country

14. Competition Landscape

  • 14.1. Market Player - Competition Matrix (By Tier and Size of companies)
  • 14.2. Market Share Analysis By Company (2016)
  • 14.3. Company Profiles (Details - Overview, Financials, Recent Developments, Strategy)
    • 14.3.1. AstraZeneca
      • 14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.1.2. Financial Overview
      • 14.3.1.3. Product Portfolio
      • 14.3.1.4. SWOT Analysis
      • 14.3.1.5. Strategic Overview
    • 14.3.2. Pfizer Inc.
      • 14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.2.2. Financial Overview
      • 14.3.2.3. Product Portfolio
      • 14.3.2.4. SWOT Analysis
      • 14.3.2.5. Strategic Overview
    • 14.3.3. Novartis AG
      • 14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.3.2. Financial Overview
      • 14.3.3.3. Product Portfolio
      • 14.3.3.4. SWOT Analysis
      • 14.3.3.5. Strategic Overview
    • 14.3.4. Merck & Co. Inc.
      • 14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.4.2. Financial Overview
      • 14.3.4.3. Product Portfolio
      • 14.3.4.4. SWOT Analysis
      • 14.3.4.5. Strategic Overview
    • 14.3.5. Bristol-Myers Squibb Company
      • 14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.5.2. Financial Overview
      • 14.3.5.3. Product Portfolio
      • 14.3.5.4. SWOT Analysis
      • 14.3.5.5. Strategic Overview
    • 14.3.6. Bayer AG
      • 14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.6.2. Financial Overview
      • 14.3.6.3. Product Portfolio
      • 14.3.6.4. SWOT Analysis
      • 14.3.6.5. Strategic Overview
    • 14.3.7. Sanofi
      • 14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.7.2. Financial Overview
      • 14.3.7.3. Product Portfolio
      • 14.3.7.4. SWOT Analysis
      • 14.3.7.5. Strategic Overview
    • 14.3.8. Boehringer Ingelheim GmbH
      • 14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.8.2. Financial Overview
      • 14.3.8.3. Product Portfolio
      • 14.3.8.4. SWOT Analysis
      • 14.3.8.5. Strategic Overview
    • 14.3.9. F. Hoffmann-La Roche Ltd.
      • 14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.9.2. Financial Overview
      • 14.3.9.3. Product Portfolio
      • 14.3.9.4. SWOT Analysis
      • 14.3.9.5. Strategic Overview
    • 14.3.10. Abbott Laboratories
      • 14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.10.2. Financial Overview
      • 14.3.10.3. Product Portfolio
      • 14.3.10.4. SWOT Analysis
      • 14.3.10.5. Strategic Overview
    • 14.3.11. Gilead Sciences, Inc.
      • 14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.11.2. Financial Overview
      • 14.3.11.3. Product Portfolio
      • 14.3.11.4. SWOT Analysis
      • 14.3.11.5. Strategic Overview
    • 14.3.12. Johnson & Johnson
      • 14.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.12.2. Financial Overview
      • 14.3.12.3. Product Portfolio
      • 14.3.12.4. SWOT Analysis
      • 14.3.12.5. Strategic Overview
    • 14.3.13. Astellas Pharma, Inc.
      • 14.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.13.2. Financial Overview
      • 14.3.13.3. Product Portfolio
      • 14.3.13.4. SWOT Analysis
      • 14.3.13.5. Strategic Overview
    • 14.3.14. Eli Lilly and Company
      • 14.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.14.2. Financial Overview
      • 14.3.14.3. Product Portfolio
      • 14.3.14.4. SWOT Analysis
      • 14.3.14.5. Strategic Overview
    • 14.3.15. Otsuka Holdings Co., Ltd.
      • 14.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.15.2. Financial Overview
      • 14.3.15.3. Product Portfolio
      • 14.3.15.4. SWOT Analysis
      • 14.3.15.5. Strategic Overview
    • 14.3.16. Takeda Pharmaceuticals Company Limited
      • 14.3.16.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.16.2. Financial Overview
      • 14.3.16.3. Product Portfolio
      • 14.3.16.4. SWOT Analysis
      • 14.3.16.5. Strategic Overview

List of Tables

  • Table 01: Global Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2015-2025
  • Table 02: Global Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Drug Class - Renin-Angiotensin System Blockers, 2015-2025
  • Table 03: Global Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Drug Class - Anti-Clotting Agents, 2015-2025
  • Table 04: Global Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Indication, 2015-2025
  • Table 05: Global Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2015-2025
  • Table 06: Global Cardiovascular Drugs Market Size (US$ Bn) Forecast, by Region, 2017-2025
  • Table 07: North America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Country, 2017-2025
  • Table 08: North America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2015-2025
  • Table 09: North America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Renin-Angiotensin System Blockers, 2015-2025
  • Table 10: North America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Anti-clotting Agents, 2015-2025
  • Table 11: North America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Indication, 2015-2025
  • Table 12: North America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2025
  • Table 13: North America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Country, 2017-2025
  • Table 14: Europe Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2015-2025
  • Table 15: Europe Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Renin-Angiotensin System Blockers, 2015-2025
  • Table 16: Europe Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Anti-clotting Agents, 2015-2025
  • Table 17: Europe Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Indication, 2015-2025
  • Table 18: Europe Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2025
  • Table 19: Europe Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Country, 2017-2025
  • Table 20: Asia Pacific Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2015-2025
  • Table 21: Asia Pacific Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Renin-Angiotensin System Blockers, 2015-2025
  • Table 22: Asia Pacific Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Anti-clotting Agents, 2015-2025
  • Table 23: Asia Pacific Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Indication, 2015-2025
  • Table 24: Asia Pacific Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2025
  • Table 25: Asia Pacific Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Country, 2017-2025
  • Table 26: Latin America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2015-2025
  • Table 27: Latin America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Renin-Angiotensin System Blockers, 2015-2025
  • Table 28: Latin America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Anti-clotting Agents, 2015-2025
  • Table 29: Latin America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Indication, 2015-2025
  • Table 30: Latin America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2025
  • Table 31: Latin America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Country, 2017-2025
  • Table 32: Middle East & Africa Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2015-2025
  • Table 33: Middle East & Africa Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Renin-Angiotensin System Blockers, 2015-2025
  • Table 34: Middle East & Africa Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Anti-clotting Agents, 2015-2025
  • Table 35: Middle East & Africa Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Indication, 2015-2025
  • Table 36: Middle East & Africa Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2025
  • Table 37: Middle East & Africa Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Country, 2017-2025

List of Figures

  • Figure 01: Global Cardiovascular Drugs Market Snapshot
  • Figure 02: Global Cardiovascular Drugs Market Size (US$ Mn) Forecast, 2017-2025
  • Figure 03: Global Cardiovascular Market Value Share, by Drug Class (2016)
  • Figure 04: Global Cardiovascular Market Value Share, by Indication (2016)
  • Figure 05: Global Cardiovascular Market Value Share, by Distribution Channel (2016)
  • Figure 07: Global Cardiovascular Market Value Share, by Region (2016)
  • Figure 06: Global Cardiovascular Drugs Market Value Share Analysis, by Drug Class, 2017 and 2025
  • Figure 08: Global Cardiovascular Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by RAS Blockers, 2015-2025
  • Figure 09: Global Cardiovascular Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Beta Blockers, 2015-2025
  • Figure 10: Global Cardiovascular Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Diuretics, 2015-2025
  • Figure 11: Global Cardiovascular Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Anti-clotting Agents, 2015-2025
  • Figure 12: Global Cardiovascular Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Antihyperlipidemics, 2015-2025
  • Figure 13: Global Cardiovascular Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Other Antihypertensive, 2015-2025
  • Figure 14: Global Cardiovascular Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Calcium Channel Blockers, 2015-2025
  • Figure 15: Global Cardiovascular Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Others, 2015-2025
  • Figure 16: Global Cardiovascular Drugs Market Attractiveness Analysis, by Drug Class 2017-2025
  • Figure 17: Global Cardiovascular Drugs Market Value Share Analysis, by Indication, 2017 and 2025
  • Figure 18: Global Cardiovascular Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Hypertension, 2015-2025
  • Figure 19: Global Cardiovascular Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hyperlipidemia, 2015-2025
  • Figure 20: Global Cardiovascular Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Coronary Artery Disease, 2015-2025
  • Figure 21: Global Cardiovascular Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Peripheral Vascular Disease, 2015-2025
  • Figure 22: Global Cardiovascular Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Antiarrhythmic, 2015-2025
  • Figure 23: Global Cardiovascular Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Others, 2015-2025
  • Figure 24: Global Cardiovascular Drugs Market Attractiveness Analysis, by Indication 2017-2025
  • Figure 25: Global Cardiovascular Drugs Market Value Share Analysis, by Distribution Channel, 2017 and 2025
  • Figure 26: Global Cardiovascular Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2015-2025
  • Figure 27: Global Cardiovascular Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2015-2025
  • Figure 28: Global Cardiovascular Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Online Pharmacies, 2015-2025
  • Figure 29: Global Cardiovascular Drugs Market Attractiveness Analysis, by Distribution Channel 2017-2025
  • Figure 30: Global Cardiovascular Drugs Market Value Share Analysis, by Region, 2016 and 2025
  • Figure 31: Global Cardiovascular Drugs Market Attractiveness Analysis, by Region
  • Figure 32: North America Cardiovascular Drugs Market Size (US$ Mn) Forecast, 2017-2025
  • Figure 33: North America Cardiovascular Drugs Market Value Share Analysis, by Country, 2017 and 2025
  • Figure 34: North America Cardiovascular Drugs Market Attractiveness Analysis, by Country
  • Figure 35: North America Cardiovascular Drugs Market Value Share Analysis, by Drug Class, 2016 and 2025
  • Figure 36: North America Cardiovascular Drugs Market Value Share Analysis, by Indication, 2016 and 2025
  • Figure 37: North America Cardiovascular Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2025
  • Figure 38: North America Cardiovascular Drugs Market Attractiveness Analysis, by Drug Class
  • Figure 39: North America Cardiovascular Drugs Market Attractiveness Analysis, by Indication
  • Figure 40: North America Cardiovascular Drugs Market Attractiveness Analysis, by Distribution Channel
  • Figure 41: Europe Cardiovascular Drugs Market Size (US$ Mn) Forecast, 2017-2025
  • Figure 42: Europe Cardiovascular Drugs Market Value Share Analysis, by Country, 2017 and 2025
  • Figure 43: Europe Cardiovascular Drugs Market Attractiveness Analysis, by Country
  • Figure 44: Europe Cardiovascular Drugs Market Value Share Analysis, by Drug Class, 2016 and 2025
  • Figure 45: Europe Cardiovascular Drugs Market Value Share Analysis, by Indication, 2016 and 2025
  • Figure 46: Europe Cardiovascular Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2025
  • Figure 47: Europe Cardiovascular Drugs Market Attractiveness Analysis, by Drug Class
  • Figure 48: Europe Cardiovascular Drugs Market Attractiveness Analysis, by Indication
  • Figure 49: Europe Cardiovascular Drugs Market Attractiveness Analysis, by Distribution Channel
  • Figure 50: Asia Pacific Cardiovascular Drugs Market Size (US$ Mn) Forecast, 2017-2025
  • Figure 51: Asia Pacific Cardiovascular Drugs Market Value Share Analysis, by Country, 2017 and 2025
  • Figure 52: Asia Pacific Cardiovascular Drugs Market Attractiveness Analysis, by Country
  • Figure 53: Asia Pacific Cardiovascular Drugs Market Value Share Analysis, by Drug Class, 2016 and 2025
  • Figure 54: Asia Pacific Cardiovascular Drugs Market Value Share Analysis, by Indication, 2016 and 2025
  • Figure 55: Asia Pacific Cardiovascular Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2025
  • Figure 56: Asia Pacific Cardiovascular Drugs Market Attractiveness Analysis, by Drug Class
  • Figure 57: Asia Pacific Cardiovascular Drugs Market Attractiveness Analysis, by Indication
  • Figure 58: Asia Pacific Cardiovascular Drugs Market Attractiveness Analysis, by Distribution Channel
  • Figure 59: Latin America Cardiovascular Drugs Market Size (US$ Mn) Forecast, 2017-2025
  • Figure 60: Latin America Cardiovascular Drugs Market Value Share Analysis, by Country, 2017 and 2025
  • Figure 61: Latin America Cardiovascular Drugs Market Attractiveness Analysis, by Country
  • Figure 62: Latin America Cardiovascular Drugs Market Value Share Analysis, by Drug Class, 2016 and 2025
  • Figure 63: Latin America Cardiovascular Drugs Market Value Share Analysis, by Indication, 2016 and 2025
  • Figure 64: Latin America Cardiovascular Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2025
  • Figure 65: Latin America Cardiovascular Drugs Market Attractiveness Analysis, by Drug Class
  • Figure 66: Latin America Cardiovascular Drugs Market Attractiveness Analysis, by Indication
  • Figure 67: Latin America Cardiovascular Drugs Market Attractiveness Analysis, by Distribution Channel
  • Figure 68: Middle East & Africa Cardiovascular Drugs Market Size (US$ Mn) Forecast, 2017-2025
  • Figure 69: Middle East & Africa Cardiovascular Drugs Market Value Share Analysis, by Country, 2017 and 2025
  • Figure 70: Middle East & Africa Cardiovascular Drugs Market Attractiveness Analysis, by Country
  • Figure 71: Middle East & Africa Cardiovascular Drugs Market Value Share Analysis, by Drug Class, 2016 and 2025
  • Figure 72: Middle East & Africa Cardiovascular Drugs Market Value Share Analysis, by Indication, 2016 and 2025
  • Figure 73: Middle East & Africa Cardiovascular Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2025
  • Figure 74: Middle East & Africa Cardiovascular Drugs Market Attractiveness Analysis, by Drug Class
  • Figure 75: Middle East & Africa Cardiovascular Drugs Market Attractiveness Analysis, by Indication
  • Figure 76: Middle East & Africa Cardiovascular Drugs Market Attractiveness Analysis, by Distribution Channel
  • Figure 77: Global Cardiovascular Drugs Market Share Analysis By Company (2016)